Exosome treatment is a method that uses very small delivery particles that cells send outward, applied to the skin. The material differs from a procedure that transfers living stem cells.
3-line summary
1. Products on the market are often distributed as cosmetics.
2. Korea's MFDS has placed exosome wording that could be mistaken as human-derived on the prohibited list for cosmetic labeling and advertising.
3. Whether it is applied or injected is confirmed first during consultation.
Particles that cells send outward
International society guidance describes these particles as membrane-enclosed particles that cells release. They cannot replicate on their own. It recommends using the name exosome only for particles confirmed to come from an intracellular pathway. Products called exosomes in the consultation room are often a broader set of particles than that.
The starting point differs from SVF (stromal vascular fraction), which places living cells, or from PRF (platelet-containing fibrin) prepared from the person's own blood. Exosome products bring in a preparation made outside the body.
| Item | Exosome product | SVF | PRF |
|---|---|---|---|
| What is used | Delivery particles made outside the body | Mixed cells collected from the person's own fat | Fibrin made from the person's own blood |
| Harvest | No harvest | Fat harvest from the abdomen, thighs, or similar sites | Venous blood draw |
| Consultation focus | Product classification and how it is used | Harvest site and whether culture is involved | Blood draw and injection response |
SVF can be followed in the guide to the cell fraction collected from fat and the SVF procedure guide, and PRF in the PRF standalone guide.
Changes discussed for the skin
Reviews of skin aging summarize the collagen-containing matrix inside the skin, the cells in the dermis that make collagen, and antioxidants. Human facial data include a small comparison in which a product was applied together with a needle procedure, and that trial received manufacturer research funding.
How it is perceived splits by skin condition, age, and lifestyle. Duration is not presented as a single fixed number.
Topical products and injection
In Korea, products labeled as exosomes are often distributed as cosmetics. Cosmetics are used by applying and rubbing. Korea's MFDS listed exosome wording that could be mistaken for an ingredient from the human body as a prohibited example in cosmetic labeling and advertising. Wording that clearly comes from outside the human body, such as plant or milk, was left as a permitted example.
U.S. regulators state that exosome products that treat disease require prior authorization. That authorization list currently leaves exosome treatment products unlisted. They have also published reports of serious adverse events from products used without authorization.
| What to check | Topical use | Injection |
|---|---|---|
| Use | Applied to the skin | Placed with a needle |
| Distribution | Common as cosmetics | Confirm classification for each product |
| Same day | Absorption after application | Needle marks, redness, swelling |
When placing it alongside a skin booster such as Rejuran that has a written authorization scope, looking at the exosome and Rejuran comparison together shows that the ingredients differ.
On the day of treatment
After confirming the product name and classification, and whether it will be applied or injected, the treatment area is chosen and disinfected. The preparation is applied or injected without fat harvest or a blood draw. If a needle is used, a pricking sensation and same-day redness and swelling follow. The schedule is set by watching how quickly the skin reaction settles.
Session count, dose, and the quote vary with the product and the area treated. A wider treatment area makes the quote larger. Pricing is explained during consultation.
Redness, swelling, and history to disclose in advance
After injection or application, temporary erythema, swelling, pain, and bruising are common. Infection and allergic reactions are also reported. The serious adverse events published by U.S. regulators are reports from products used without authorization.
Pregnancy or breastfeeding, active infection at the treatment site, anticoagulants or immunosuppressants, and allergy to the relevant ingredient are disclosed in advance. Whether to proceed is decided on the spot. For shared precautions, see the procedure safety information.
Questions that identify the product and its source
Asking the following as written distinguishes the product and how it is used.
- □ Whether today's product is classified as a cosmetic, or as a drug or medical device
- □ Whether it is topical use or injection
- □ Whether the raw material is human-derived, or plant- or milk-derived
- □ Pregnancy or breastfeeding, active infection, anticoagulants or immunosuppressants, allergy
- □ Whether it will be done on the same day as Rejuran, autologous-cell, or blood-based procedures
Frequently asked questions
Q1. Does the procedure hurt?
If a needle is used, there is a pricking sensation, and same-day redness and swelling follow. If it is only applied, the day is completed without needle marks.
Q2. How many sessions are needed?
The number of sessions is set to the product and skin condition. The next appointment is decided after seeing the response to the previous session.
Q3. How long do the effects last?
Changes are observed in later sessions rather than immediately after treatment. Duration is not decided from looking in the mirror on the day of treatment alone.
Q4. Can it be combined with Rejuran or a blood-based procedure?
The ingredients differ. Rejuran is fragments of fish DNA, and a blood-based procedure uses the person's own blood draw. Whether to proceed on the same day is decided after seeing the skin response.
Q5. Who should not receive it?
If you are pregnant or breastfeeding, have an active infection at the treatment site, take anticoagulants or immunosuppressants, or have an allergy to the relevant ingredient, disclose this in advance. That day's session is postponed or switched to another procedure.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Source materials
- International Society for Extracellular Vesicles guidelines (MISEV2023), PMID 38326288 — Abstract and public-version nomenclature table. Membrane-bound particles that cells release; the name exosome is recommended only when an intracellular pathway is confirmed. A methods-consensus document, not a trial that measured skin aesthetic effects. A subsequent corrigendum (PMID 38726651) was attached.
- Skin aging review, PMID 35809187 — Abstract. Summarizes the collagen matrix, epidermis, fibroblasts, and antioxidants. A review, not an original human trial. The title's ‘reversal’ is stronger than the speculative sentence in the abstract. No author conflicts of interest (abstract).
- Facial photoaging comparison trial, PMID 40414798 — Abstract and PMC full text. 15 people; after three sessions of radiofrequency microneedling, one side received plasma and the other a topical exosome. Manufacturer (Benev) research funding. Non-randomized; the body states that clinical statistical analysis was omitted because the sample was small. Not data that isolated the effect of the exosome alone.
- Korea's MFDS press reference (2025.1.21.) — Expansion of prohibited expressions in cosmetic labeling and advertising — PDF body. Prohibits expressions for human-derived ingredients (exosomes, etc.); prohibited examples ‘exosome cosmetics · exosome’; permitted examples ‘plant exosome · milk exosome’. A labeling and advertising guideline; it does not evaluate treatment effects.
- Korea's MFDS Cosmetics Labeling and Advertising Management Guidelines (2025.8.14. Guidance for Civil Petitioners) — PDF body prohibited-expression table. The same exosome prohibited and permitted examples as the press release. Guidance for businesses.
- U.S. Food and Drug Administration consumer alert (2020.7.22., page updated 2024.4.9.) — Body. States that exosome products that treat a disease or condition require authorization, and that authorized exosome products have not been placed on that list. U.S. regulatory scope.
- U.S. Food and Drug Administration safety notification on exosome products (2019.12.6.) — Body. Reports of serious adverse events from products used without authorization in Nebraska. A U.S. case; not a tally of adverse events for a specific product in Korea.
Related reading
Sources
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.
